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Abstract
Background: Epidermal growth factor (EGF) is critical in cancer process. EGF and EGF receptor (EGFR) interaction plays 
a pivotal role in cell proliferation, differentiation, and tumorigenesis of epithelial tissues. Variations of the EGF +61G/A 
(rs4444903) may lead to an alteration in EGF production and/or activity, which can result in individual susceptibility to 
brain glioma. The purpose of this study was to investigate the potential association between EGF +61G/A and brain 
glioma in a Chinese population.
Methods: In this study, we analyzed single nucleotide polymorphism of EGF +61G/A in 677 patients with glioma and 
698 gender- and age-matched controls. Genotyping was performed by polymerase chain reaction-ligation detection 
reaction (PCR-LDR) method.
Results: The A allele (minor Allele) was 33.0% in cases and 27.3% in controls. The additive model was more powerful to 
reveal the association in our study than that of recessive and dominant model. Our data showed the genotype G/A and 
A/A was associated with increased risk for glioma (adjusted OR = 1.48, 95%CI: 1.17-1.87, p = 0.001 for G/A, adjusted OR 
= 1.81, 95%CI: 1.20-2.72, p = 0.005 for A/A, respectively), and for glioblastoma (adjusted OR = 1.51, 95%CI: 1.06-2.17, p = 
0.024 and adjusted OR = 2.35, 95%CI: 1.34-4.15, p = 0.003, respectively). The A allele significantly increased glioma risk 
(OR = 1.31, 95%CI: 1.11-1.55, p = 0.001). The additive model (G/G vs G/A vs A/A) showed that both G/A and A/A 
genotype increased glioma risk (adjusted OR = 1.40, 95% CI: 1.17-1.66, p = 0.0002).G/A and A/A genotypes or EGF +61 
A allele increased risk in both low and high WHO grade glioma. Non-smokers with G/A and A/A genotype showed 
increased glioma risk compared with G/G genotype (adjusted OR = 1.72, 95%CI: 1.29-2.30, p = 0.0002 and adjusted OR 
= 1.81, 95%CI: 1.10-2.99, p = 0.020, respectively). This association was not found in ever- or current-smokers.
Conclusions: Our study indicated that G/A and A/A genotypes or EGF +61 A allele were associated with higher glioma 
risk in Chinese. This is in contrast with previous studies which reported G allele as a risk factor of glioma in Caucasian. 
The role of EGF +61 A/G polymorphism in glioma susceptibility needs further investigation.
Background
Gliomas are a particularly lethal solid tumor arising from
support cells in the central nervous system, which can be
divided into astrocytic tumors, oligodendrogliomas, and
oligoastrocytomas. These are then graded into 4 histolog-
ical degrees of malignancy, according to the WHO classi-
fication [1]. Oligodendrogliomas and oligoastrocytomas
are tiered into grade II, and anaplastic is grade III lesions.
Astrocytomas, which are tumors composed predomi-
nantly of neoplastic astrocytes, amount to 80-85% of all
gliomas. It is graded from low (grade I) to high (grade IV),
according to hallmarks of the tumor histological aberra-
tions [2]. Grade IV astrocytomas are known as glioblas-
toma multiforme (GBM), the most common and lethal
form of malignant gliomas. The median survival time of
GBM was only 10 months for those no older than 65 and
3.5 months for 65 or older [3]. However, recent research
indicated that age groups (<65 and ≥65 years) was not
associated with survival time, with median survival 13
months and 15 months, respectively [4]. Despite the
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development of therapy technology, the death rate of
glioblastoma patients decreases a little, which indicates
that the survival time of the most common and aggressive
form of glioma in adults is very poor [5]. Previous studies
suggested that some factors like workplace, dietary, and
other personal and residential exposures might result in
gliomas [6], as well as the genetic factors such as single
nucleotide polymorphisms (SNPs) [7].
Epidermal growth factor (EGF), first isolated in 1962
[8], is encoded by a single gene on chromosome 4q25-q27
[9]. EGF has a profound effect on the differentiation and
is a potent mitogenic factor for a variety of cultured cells
of both ectodermal and mesodermal origin [10]. Its
receptor, EGFR, is one of the first human EGF receptor
(HER) family members discovered. In normal brain
development, EGFR-mediated signaling plays a critical
role. The EGFR family and its ligands are variably
expressed from embryogenesis, throughout brain devel-
opment, and into adulthood. They are involved in the
proliferation, migration, differentiation, and survival of
all central nervous system cell types and their precursors
[11].
EGFR ligands such as EGF are often overexpressed in
gliomas [12]. Bello et al. [13] observed that the postopera-
tive levels of EGF decreased in all patients who under-
went surgery and the entity of the decrease seemed to be
well correlated with the extent of the tumoral resection.
Shahbazi et al. [14] tested genetic polymorphisms in EGF
in 135 white European patients with malignant mela-
noma and in 99 healthy white European controls. They
identified a 61A-G (rs4444903) substitution in the 5-
prime untranslated region of the EGF gene. Cells from
individuals homozygous for the 61A allele produced sig-
nificantly less EGF than cells from 61G homozygote or A/
G heterozygote. Compared with the A/A genotype, G/G
was significantly associated with increased risk of malig-
nant melanoma. However, association studies on the
polymorphism in various cancers had shown conflicting
results [15-19].
Recent study showed that this polymorphism may
causes expression difference and enhances glioma sus-
ceptibility [20]. Vauleon et al. [21] showed that the 61 A/
G polymorphism was functional, in that the G allele pro-
moter was 40% more active than the A variant (p < 0.001).
However, analysis of 209 GBM patients and 214 control
subjects did not confirm that 61 A/G polymorphism was
a significant risk factor for GBM, despite a trend for
higher G/G frequency in the patients. Costa et al. [20]
studied 197 glioma patients and 570 cancer-free individu-
als; they found that the G allele conferred higher risk for
gliomas, glioblastomas, and oligodendrogliomas. G/G
genotype was significantly associated with increased risk
for gliomas. In order to clarify the significance of this
genetic polymorphism in glioma susceptibility, we did a
case-control study of 677 glioma patients and 698 cancer-
free controls in a Chinese population.
Methods
Study population
The population in this case-control study was similar to
Liu et al. [22]. 677 patients diagnosed with histopatholog-
ically confirmed glioma were enrolled. All subjects,
including case and control groups, were genetically unre-
lated ethnic Han Chinese and were from Shanghai and
the surrounding provinces (Zhejiang, Jiangsu and Anhui)
in east China. Patients were consecutively recruited
between October 2004 and May 2006 in the Department
of Neurosurgery at Huashan Hospital of Fudan University
(Shanghai, China) with no restrictions of age, gender and
histology. The research protocol was reviewed and
approved by the Fudan University Ethics Committee for
Human Subject Research.
The 698 cancer-free control subjects included trauma
outpatients (20%) from the Emergency Medical Centre
and hospital visitors (80%) who came to the health exam-
ination clinic for an annual check-up at the same hospital
(Huashan Hospital) during the same period. The exclu-
sion criteria for healthy subjects included central nervous
system-related disease, self-reported history of any can-
cer and previous radiotherapy and chemotherapy for
unknown disease conditions. All the control subjects
were frequency matched to the cases on age (± 5 years),
gender and residence area (urban or rural).
Each eligible subject was interviewed by a trained per-
sonnel who was not aware of the case and control with a
structured questionnaire to obtain detailed information
on demographic factors, family history of cancer (fmc),
smoking status, and health characteristics. Fmc was
defined as any self-reported cancer in the first-degree rel-
atives (parents, siblings, or children). Never-smokers
were defined as those who had smoked less than one cig-
arette per day and less than 1 year in their lifetime. Smok-
ers were classified into ever-smokers and current-
smokers. As a result, 806 glioma cases and 910 control
subjects were recruited without the restrictions of age,
sex and glioma histology. Among all participants, DNA
samples and questionnaires were available from 677 cases
and 698 control subjects representing an 84.0% and 76.7%
of all eligible case and control subjects, respectively. A
blood specimen was collected from each subject after the
informed consent was obtained.
DNA extraction and genotyping
3-5 ml venous blood was collected from each subject.
EDTA-containing tubes were used to collect blood sam-
ples and then Qiagen Blood Kit (Qiagen, Chatsworth,
CA, USA) was applied to extract genomic DNA. Poly-
merase chain reaction-ligation detection reaction (PCR-Wang et al. BMC Cancer 2010, 10:221
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LDR) method was used to perform the genotyping.
EGF+61 specific primers were: forward primer 5'-
TAAAGGAAAGGAGGTGGAGCC-3', and reverse
primer 5'-TGTGACAGAGCAAGGCAAAGG-3'. PCR
was conducted on the ABI 9600 (Applied Biosystems,
Foster City,CA,USA) in a system with total volume of 15
μl containing 1 ul genomic DNA, 1.5 μl 10×PCR Buffer,
0.13 μM each primer, 0.2 mM dNTP, 0.25 μl Taq DNA
polymerase (Qlagen Gmbh, Hllden, Germany) and 7.5 μl
H2O. The cycling parameters were: 94°C for 1 min; 35
cycles at 94°C for 10 s, 56°C for 20 s, 72°C for 40 s; and a
final extension step at 72°C for 3 min. The probes for LDR
were: 5'-P-GCTGGAACTTTCCATCAGTTCT-FAM-
3'with common phosphorylated 5'- end and 6-carboxyX-
uorescein(FAM) labeled 3'-end, the G-specific probe 5'
TTCAGCCCCAATCCAAGGGATGTG-3', the A-spe-
cific probe 5'-tttttTTCAGCCCCAATCCAAGGGAT-
GTA-3'. For each PCR product, the ligation reaction was
performed in a final volume of 10 ul including 2 μl of PCR
product, 1 μl 10×Taq DNA ligase buffer, 0.02 μM of probe
mixture, 5 U Taq DNA ligase (New England Biolabs, Bev-
erly, Mass, USA) and 6 μl H2O. The LDR parameters were
as follows: 25 cycles at 94°C for 30 s and 55°C for 4 min.
The LDR reaction products were analyzed on ABI 377
DNA Sequencer (Applied Biosystems). To confirm the
accuracy of PCR-LDR genotyping method, direct DNA
sequencing of randomly selected PCR products was per-
formed. The proportion of the sequencing samples were
about 5%. The results of the PCR-LDR genotyping
showed 100% concordance to direct DNA sequencing of
the randomly selected PCR products.
Statistical analysis
The Fisher's exact Chi-square test was first used to com-
pare the frequency distribution of age, gender, smoking
status and fmc between cases and controls. Hardy-Wein-
berg equilibrium (HWE) was tested by the χ2-test for
goodness of fit using a web-based program http://
ihg.gsf.de/cgi-bin/hw/hwa1.pl. To evaluate the associa-
tion between EGF+61 G/A polymorphism and glioma
risk, odds ratios (ORs) and 95% confidence intervals (CIs)
were estimated by multivariate logistic regression analy-
ses, adjusted by age and sex, or adjusted by age, sex, fmc,
or adjusted by age, sex, smoking status and fmc, respec-
tively. The genotype-smoking interaction was calculated
by introducing an interaction term into the multivariate
logistic regression which was adjusted by age, sex, fmc,
smoking status and genotype. The patients were stratified
into three subgroups according to histology: glioblas-
toma, astrocytomas (including diffuse astrocytomas, ana-
plastic astrocytomas or other astrocytomas except for
glioblastoma) and other gliomas (including oligodendro-
glimas, enpendymomas or mixed glioma). Patients were
also grouped with WHO grade to glioma: WHO I, WHO
II, WHO III and WHO IV. Subgroup analysis according
to histology and WHO grade were performed to estimate
the specific ORs. Analyses were performed using the
software SPSS 16.0 (SPSS Inc., Chicago, IL, USA). All P
values were two-sided, and a P value < 0.05 was consid-
ered significant. QUANTO (version 1.2.4) software was
used to calculate the statistic power and sample size. The
power was computed as the probability of detecting an
association between the EGF +61A/G polymorphism and
glioma at the 0.05 significance level for the two-sided test,
assuming an odds ratio of 1.2, 1.3, 1,4 in different genetic
models, respectively. The sample size was calculated with
the two-sided test in additive model, under the condition
of 1.03 controls per case, the power and minor allele fre-
quency (MAF) equal to 0.8 and 0.273, respectively.
Results
Characteristics of the study population
677 cases and 698 cancer-free controls were enrolled in
our study. The genotyping was successful for EGF +61A/
G in 672 glioma patients and 693 controls. The distribu-
tion of EGF+61 allele frequencies in the control group
was in Hardy-Weinberg equilibrium (p>0.999). The char-
acteristics of case patients and control subjects are sum-
marized in Table 1. The mean age was 41.6 years (± 16.3
years, ranging from 2-79 yeas) for the cases and 39.6 years
(± 18.3 years, ranging from 1-86 years) for the controls.
Among 677 case patients, 256 (37.8%) had astrocytomas,
220 (32.5%) had glioblastoma and 201 (29.7%) had other
gliomas. There were no significant differences on age and
gender between the cases and the controls (p = 0.355 for
age stratification and 0.141 for gender). In addition, no
significant differences between the cases and the controls
in smoking status and fmc were found (Table 1). The A
allele was 33.0% in cases and 27.3% in controls. The fre-
quencies of the G/G, G/A, and A/A genotypes of EGF
+61 G/A were 52.8%, 39.8% and 7.4% in controls, and
44.3%, 45.4% and 10.3% in cases, respectively. The geno-
typing result showed that in this Chinese population the
frequency of EGF+61G was higher than that of Cauca-
sians. This is in accordance with the HapMap result
(Table 2), with G allele frequency is higher in Asian, but
lower in Caucasian compared with A allele.
Association between EGF +61 SNP and risk of glioma
The genotype distributions of cases and control subjects
are summarized in Table 3. Overall, the A allele was asso-
ciated with increased risk for glioma compared with G
allele (OR = 1.31, 95% CI: 1.11-1.55, p = 0.001).
The smoking status information of 93 subjects was
missing. The sample size decreased when adjusting for
sex, age, fmc and smoking status, and the number of
c o v a r i a t e s  m a y  a f f e c t  t h e  r e s u l t s.  T o o  m a n y  c o v a r i a t e s
may result in overfitting the logistic regression model, asWang et al. BMC Cancer 2010, 10:221
http://www.biomedcentral.com/1471-2407/10/221
Page 4 of 13
well as decrease precision of the estimation of the vari-
able interested [23]. Thus, we calculated three ORs for
every independent analysis with different adjustment
strategies, which provided more information for different
stratified population. Using G/G genotype as reference,
A/A and G/A genotypes were both associated with
increased risk for glioma (adjusted OR** = 1.81, 95%CI:
1.20-2.72 and adjusted OR** = 1.48, 95%CI: 1.17-1.87,
respectively). A/A was associated with glioma risk
adjusted for gender, age, smoking status, fmc (adjusted
OR** = 1.50, 95%CI: 1.01-2.22, p = 0.043) under recessive
genetic model, whereas it failed to reach significance in
the univariate analysis (Table 3). Dominant genetic model
showed that G/A+A/A was significantly associated with
the increased risk of glioma in univariate analysis (OR =
1.41, 95%CI: 1.14-1.74, p = 0.002) and multivariate model
(adjusted OR** = 1.53, 95%CI: 1.22-1.91, p = 0.0002).
Additive model showed that from G/G to A/A the risk
significantly increased (adjusted OR** = 1.40, 95%CI:
1.17-1.66, p = 0.0002).
The power of additive model
Table 4 showed the statistic power to demonstrate the
association between EGF +61 G/A polymorphism and
glioma if the OR was 1.3, 1.4, 1.5 under dominant, reces-
sive, log additive genetic model, respectively. Generally,
the power increased with OR, and the log additive model
was the most powerful under a fixed OR. Under the con-
dition that MAF was 0.273, sample size was 672 (1.03
control per case), the significant value was 0.05 (type I
error = 0.05), and the OR was 1.40 in additive model, the
predicted power was 0.981. However, the power was
0.973 if OR = 1.53 in dominant model. Thus, the additive
model is the most powerful genetic model to reveal the
association in our study; we then used this model in the
following stratification analysis. A statistical power
Table 1: Charcteristics of selected patients with glioma and controls
Variable Patients
(n = 677)
No.(%)
Controls
(n = 698)
No.(%)
P value*
Gender 0.141
Male 400(59.1) 384(55.0)
Female 277(40.9) 314(45.0)
Age(years) 0.355
Children(≤18) 69(10.2) 60(8.6)
Adults(>18) 608(89.8) 638(91.4)
Smoking statusa 0.093
Never 386(65.8) 454(65.3)
Ever 72(12.3) 111(16.0)
Current 129(22.0) 130(18.7)
Family history of cancer 0.056
No 566(83.6) 609(87.2)
Yes 111(16.4) 89(12.8)
Histology
Astrocytomasb 256(37.8)
Glioblastoma 220(32.5)
Other gliomasc 201(29.7)
WHO
WHOI 61(9.0)
WHOII 236(34.9)
WHOIII 118(17.4)
WHOIV 262(38.7)
*Two-sides χ2 test
a Smoking status information was absent for 90 patients and 3 controls
b Astrocytomas including diffuse astrocytomas, anaplastic astrocytomas, and other astrocytomas except for glioblastoma.
c Other gliomas including oligodendrogliomas, ependymomas, medulloblastoma, gliomatosis cerebri or mixed gliomasWang et al. BMC Cancer 2010, 10:221
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Table 2: Distribution of EGF +61 G/A polymorphism in healthy control populations according to NIEHS and previous 
research
N Genotypes Alleles ethnicity
GG(%) GA(%) AA(%) G(%) A(%)
Present study 693 366(52.8) 276(39.8) 51(7.4) 1008(72.7) 378(27.3) Asian
Previous study
Chinese[32] 194 92(47.4) 84(44.3) 16(8.4) 270(69.6) 118(30.4) Asian
Chinese[47] 212 100(47.2) 93(43.9) 19(9.0) 293(69.1) 131(30.9) Asian
Chinese[48] 660 314(47.6) 289(43.8) 57(8.6) 917(69.5) 403(30.5) Asian
Chinese[49] 206 98(47.6) 89(43.2) 19(9.2) 285(69.2) 127(30.8) Asian
Chinese[50] 186 96(51.6) 73(39.3) 17(9.1) 265(71.2) 107(28.8) Asian
Chinese[51] 654 328(50.2) 264(40.4) 62(9.5) 920(70.3) 388(29.7) Asian
Japanese[18] 450 215(47.8) 188(41.8) 47(10.4) 618(68.7) 282(31.3) Asian
Korean[31] 169 87(51.5) 68(40.2) 14(8.3) 242(71.6) 96(28.4) Asian
Korean[35] 432 198(45.8) 185(42.8) 49(11.3) 581(67.2) 283(32.8) Asian
Mean for Asian# 48.5(46.9-50.1) 42.2(40.8-43.6) 9.3(8.6-10.1) 69.6(68.6-70.6) 30.4(29.4-31.4)
Indian[15]* 190 34(17.9) 87(45.8) 69(36.3) 155(40.8) 225(59.2) Indian
Danish[52]* 81 15(19.0) 39(48.0) 27(33.0) 69(43.0) 93(57.0) Caucasian
British[53]* 669 112(16.7) 338(50.5) 219(32.8) 562(42.0) 776(58.0) Caucasian
American[54]* 232 30(12.9) 118(50.9) 84(36.2) 178(38.4) 286(61.6) Caucasian
Portuguese[20]* 570 131(23.0) 266(46.7) 173(30.3) 528(46.3) 612(53.7) Caucasian
Cadadian[55]* 447 72(16.0) 201(45.0) 174(39.0) 345(38.6) 549(61.4) Caucasian
Italian[56]* 255 45(17.6) 117(45.9) 93(36.5) 207(40) 303(60) Caucasian
Australian[19]* 2646 446(16.9) 1317(49.8) 883(33.4) 2209(41.7) 3083(58.3) Caucasian
Portuguese[57]* 389 89(23.0) 180(46.0) 120(31.0) 358(46.0) 420(54.0) Caucasian
Northern 
European[14]*
99 20(20.2) 47(47.5) 32(32.3) 87(43.9) 111(56.1) Caucasian
# Mean for 
Caucasian
18.3(16.1-20.6) 47.6(46.1-49.1) 34.1(32.1-36.1) 42.1(40.1-44.1) 57.9(55.9-59.9)
Brazilian[58] 56(28.00) 92(46.00) 52(26.00) 204(51.00) 196(49.00) Brazilian
NIEHS data
CHB GENO PANEL 45 20(44.4) 17(37.8) 8(17.8) 57(63.3) 33(36.7) Asian
JPT GENO PANEL 44 24(54.5) 19(43.2) 1(2.3) 67(76.1) 21(23.9) Asian
YRI GENO PANEL 60 34(56.7) 24(40.0) 2(3.3) 92(76.7) 28(23.3) Sub-Saharan 
African
CEU GENO 
PANEL*
60 10(16.7) 27(45.0) 23(38.3) 47(39.2) 73(60.8) European
Genotype frequencies and corresponding allele frequencies for EGF t61 G/A were shown for analyzed populations (refSNP ID: rs4444903). NIEHS, 
National Institute of Environmental Health Sciences; CHB, Han Chinese in Beijing, China; JPT, Japanese in Tokyo, Japan; YRI, Yoruba in Ibadan, 
Nigeria; and CEU, Utah residents with northern and western European ancestry.
* P < 0.05, compared with the present study.
# Mean (95%CI)Wang et al. BMC Cancer 2010, 10:221
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greater than 80% was obtained if the sample size was over
323 and 537 in additive model with OR equal to 1.40 and
1.30, respectively.
Association between EGF +61 SNP and risk of glioma 
stratified by smoking status
Smokers were grouped as never-, ever-, and current-
smokers as described above. In never-smokers, the A
allele showed an increased association with the risk of
glioma compared with G allele (OR = 1.47, 95%CI: 1.19-
1.81, p = 0.0003), but no association were found in ever-
and current-smokers (Table 5). For the comparison of dif-
ferent genotypes, the significant association was found
only in the never-smokers. Individuals with G/A and A/A
genotype showed increased glioma risk compared with
G/G genotype when adjusted for sex-, age-, fmc- , with
OR** = 1.72, 95% CI:1.29-2.30, p = 0.0002 and OR** =
1.81, 95%CI: 1.10-2.99, p = 0.020, respectively (Table 5).
The  P  trend for G/G vs G/A vs A/A was 0.0003, the
glioma risk significantly increased under additive genetic
model (adjusted OR** = 1.49, 95%CI: 1.20-1.84). No asso-
ciation of EGF +61 G/A and the glioma risk in ever-
smokers and current-smokers were found for different
genetic comparisons (Table 5). However, this might result
from the small sample size for ever- and current-smokers.
The p-value for EGF +61 G/A genotype-smoking interac-
tion was 0.617. The result indicated that no significant
interaction existed between EGF +61 G/A genotypes and
smoking.
Association between EGF +61 G/A and risk of glioma 
stratified by histology
G/A and A/A genotypes were significant risk factors in
glioblastoma, with adjusted OR** = 1.51, 95%CI: 1.06-
2.17, p = 0.024 and adjusted OR** = 2.35, 95%CI: 1.34-
4.15, p = 0.003, respectively. No association was found in
astrocytomas (Table 6). For other gliomas, which includ-
ing oligodendroglimas, enpendymomas and mixed
glioma, G/A was a risk factor in both univariant logistic
regression (OR = 1.50, 95% CI:1.08-2.10, p = 0.017) and
multivariant analysis (adjusted OR** = 1.96, 95% CI:1.08-
3.58, p = 0.028). However, the A/A genotype significantly
increased other gliomas risk in multivariant model
(adjusted OR** = 1.71, 95% CI: 1.20-2.45, p = 0.003), but
failed to reach significance in univariant analysis. In the
additive genetic model analysis, the P trend for G/G vs G/
A vs A/A showed that the risk significantly increased
both in glioblastoma and other gliomas, with adjusted
OR** = 1.53, 95% CI: 1.18-1.97, P  trend = 0.001 and
adjusted OR** = 1.51, 95% CI:1.17-1.95, P trend = 0.002,
respectively. The allelic analysis showed that the A allele
was a risk factor for glioblastoma (OR = 1.42, 95%CI:
1.13-1.79, p = 0.003) and other gliomas (OR = 1.37,
95%CI: 1.08-1.75, p = 0.009), but not a risk factor for
astrocytomas (Table 6).
Association between EGF +61 G/A and risk of glioma 
stratified by WHO grade
G/A genotype was found to be associated with higher risk
for grade II (adjusted OR** = 1.52, 95%CI: 1.09-2.13, p =
0.013) and grade IV glioma (adjusted OR** = 1.59, 95%CI:
1.14-2.22, p = 0.006). G/A genotype was also found to be
associated with grade I glioma in multivariant model
(adjusted OR** = 1.92, 95%CI: 1.03-3.61, p = 0.041).
Importantly, A/A genotype increased the risk for grade
IV by more than 2-fold (adjusted OR** = 2.65, 95%CI:
1.58-4.45, p = 0.0002).
In additive model, the glioma risk increased signifi-
cantly in WHO grade I (adjusted OR** = 1.69, 95%CI:
1.09-2.61,  P  trend = 0.018), grade II (adjusted OR** =
1.37, 95%CI: 1.07-1.75, P trend = 0.012), and grade IV
(adjusted OR** = 1.62, 95%CI: 1.28-2.04, P trend < 0.001).
A allele was associated with glioma risk for grade II and
IV (OR = 1.30, 95%CI: 1.03-1.62, p = 0.025 and OR = 1.50,
95%CI: 1.22-1.86, p = 0.0002, respectively).
Both G/A and A/A genotypes increased glioma risk for
low grade (WHO I+ II) using G/G as reference (adjusted
OR** = 1.59, 95%CI: 1.17-2.16, p = 0.003 and adjusted
OR** = 1.78, 95%CI: 1.04-3.03, p = 0.034, respectively). In
additive model, G/A and A/A genotype increased low
grade glioma risk gradually (adjusted OR** = 1.43, 95%CI:
1.14-1.79, P trend = 0.002). The allelic analysis indicated
that allele A was a risk factor for low grade glioma (OR =
1.32, 95%CI: 1.07-1.63, p = 0.008). G/A and A/A geno-
types also increased high grade gliomas (WHO III+ IV)
risk, as well as the result under additive genetic model
(Table 7). A allele increased glioma risk in high grade
glioma (OR = 1.30, 95%CI: 1.07-1.58, p = 0.007).
Discussion
Carcinogenesis of glioma is considered to be a process
affected by complicated factors. Environmental factors
had been a focus in previous studies, however, except
therapeutic ionizing radiation; no other environmental
factors had been shown to be associated with glioma sus-
ceptibility [24]. Compared with other cancer types,
knowledge about the role of genetic SNP in glioma is rela-
tively limited.
EGF, a 6,045-Da single chain polypeptide which acti-
vates several signaling pathways such as ras/raf/MAPK
and phosphatidylinositol-3-kinase (PI3K) [25], is of spe-
cial importance in regulating cell proliferation, migration,
adhesion, and inflammatory processes [26]. High expres-
sion of EGF had been detected in some cancer tissues,
such as gallbladder cancer [15] and glioblastoma [27]. As
an important receptor of EGF with high affinity, EGFRWang et al. BMC Cancer 2010, 10:221
http://www.biomedcentral.com/1471-2407/10/221
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was often overexpressed in glioma cells. Amplification of
EGFR gene was shown in half of the glioblastomas, as
well as overexpression of EGFR mRNA and protein [28].
The overexpression related to a poorer prognosis in
glioma patients [29]. These previous studies suggested
that overexpression of EGF and EGFR might affect cell
activities in brain tissues, abnormity of which may con-
tribute to the glioma.
How does EGF +61 polymorphism affect the character-
istic of EGF? This polymorphism had been proved to be
functionally significant in individual variability of EGF
expression. Shahbazi et al. [14] identified that cells from
61 A/A homozygous individuals produced significantly
less EGF than cells from G/G (p = 0.0004) or G/A (p =
0.001) individuals. Tanabe et al. [30] showed that with
EGF +61G, transcription product had significant longer
(more than 2-fold) half-life than 61A allele. Serum EGF
levels were 1.8-fold higher in G/G hepatocellular carci-
noma patients with cirrhosis than A/A patients, and liver
EGF levels were 2.4-fold higher in G/G patients than A/A
patients. EGF+61G enhanced risk of hepatocellular carci-
noma.
However, frequencies of EGF +61G allele were diverse
among different subpopulation. Comparing to MAF of G
allele in European population, the Chinese population
occupy 0.633 of G allele (data shown in NCBI SNP data-
base http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs =
4444903) (Table 2). We also compared the frequencies of
the genotypes and alleles between control group in the
present study and previous study on this SNP. Table 2
Table 3: Analysis of association between EGF+61 polymorphism and risk of glioma
Case(%) 
N = 672
Control(%) 
N = 693
Crude 
P-value
Crude 
OR(95%CI)
Adjusted 
P*-value
Adjusted 
OR*(95%CI)
Adjusted 
P**-value
Adjusted 
OR**(95%CI)
Genotype
GG 298(44.34) 366(52.81) 1(Reference) 1(Reference) 1(Reference)
GA 305(45.39) 276(39.83) 0.007 1.36(1.09-1.70) 0.005 1.38(1.10-1.73) 0.001 1.48(1.17-1.87)
AA 69(10.27) 51(7.36) 0.011 1.66(1.12-2.46) 0.012 1.660(1.12-2.46) 0.005 1.81(1.20-2.72)
Allele#
G 901(67.04) 1008(72.73) 1(Reference)
A 443(32.96) 378(27.27) 0.001 1.31(1.11-1.55)
Dominant
GG 298(44.34) 366(52.81) 1(Reference) 1(Reference) 1(Reference)
GA+AA 374(55.66) 327(47.19) 0.002 1.41(1.14-1.74) 0.001 1.42(1.15-1.76) 0.0002 1.53(1.22-1.91)
Recessive
GG+GA 603(89.73) 642(92.64) 1(Reference) 1(Reference) 1(Reference)
AA 69(10.27) 51(7.36) 0.059 1.44(0.99-2.10) 0.066 1.43(0.98-2.09) 0.043 1.50(1.01-2.22)
Additive
GG 298(44.34) 366(52.81) 0.001 1.32(1.12-1.56) 0.001 1.33(1.12-1.57) 0.0002 1.40(1.17-1.66)
GA 305(45.39) 276(39.83)
AA 69(10.27) 51(7.36)
*adjusted for age and sex
**adjusted for age, sex, family history of cancer (fmc) and smoking status
# the adjusted OR was not appropriated for the allele comparison
Table 4: Power of different genetic models
Model OR 1.3 1.4 1.5
Log additive 0.880 0.981 0.998
Dominant 0.677 0.873 0.962
Recessive 0.270 0.417 0.571
Power were calculated under the condition of Minor Allele Frequency (MAF) = 0.273, sample size = 672 (1.03 control per case), type I error(α) 
= 0.05.Wang et al. BMC Cancer 2010, 10:221
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Table 5: Stratified analysis of association by Smoking status between the genotypes (alleles) and risk of glioma
Case/
control
Crude 
p-value
Crude 
OR(95%CI)
Adjusted 
P*-value
Adjusted 
OR*(95%CI)
Adjusted 
P**-value
Adjusted 
OR**(95%CI)
Never genotype GG 148/239 1(Reference) 1(Reference) 1(Reference)
GA 193/180 0.0002 1.73(1.30-2.31) 0.0002 1.73(1.29-2.31) 0.0002 1.72(1.29-2.30)
AA 40/35 0.016 1.85(1.12-3.04) 0.018 1.82(1.11-3.00) 0.020 1.81(1.10-2.99)
Genetic 
model
additive 0.0002 1.50(1.21-1.86) 0.0003 1.49(1.20-1.85) 0.0003 1.49(1.20-1.84)
Allele G 489/658 1(Reference) #
A 273/250 0.0003 1.47(1.19-1.81)
Ever genotype GG 31/55 1(Reference) 1(Reference) 1(Reference)
GA 35/45 0.311 1.38(0.74-2.57) 0.395 1.32(0.70-2.51) 0.527 1.23(0.64-2.36)
AA 6/8 0.625 1.33(0.42-4.19) 0.905 1.07(0.34-3.43) 0.941 1.05(0.32-3.37)
Genetic 
model
additive 0.359 1.25(0.78-2.00) 0.572 1.15(0.78-1.87) 0.684 1.11(0.68-1.81)
Allele G 97/155 1(Reference) #
A 47/61 0.373 1.23(0.78-1.95)
Current genotype GG 68/70 1(Reference) 1(Reference) 1(Reference)
GA 45/51 0.718 0.91(0.54-1.53) 0.874 0.96(0.56-1.63) 0.878 0.96(0.56-1.63)
AA 16/7 0.077 2.35(0.91-6.08) 0.092 2.28(0.88-5.96) 0.090 2.29(0.88-5.99)
Genetic 
model
additive 0.275 1.23(0.85-1.80) 0.254 1.25(0.85-1.83) 0.249 1.25(0.85-1.84)
Allele G 181/191 1(Reference) #
A 77/65 0.259 1.25(0.85-1.84)
*adjusted for age and sex
**adjusted for age, sex and fmc
# the adjusted OR was not appropriated for the allele comparison
p-value for genotype-smoking interaction was 0.617
summarized the distribution of EGF +61 G/A polymor-
phism in different healthy control populations which fit
in HWE except the study of Lim et al. [17]. The frequency
of the EGF +61A allele in the present study was 27.3%,
which was similar to the frequency observed in Chinese
controls (30%-31%). The frequency of EGF +61A allele
was about 23.9%-32.8% in Asians, which was different
from that of Caucasians (53.7%-61.6%) (Table 2). There-
fore, constitutive EGF expression may be different in dif-
ferent ethnic groups, which might lead to discrepancy
results of association studies in different ethnic groups.
Lim et al. [17] reported somewhat different distribution
of EGF genotype in Korea healthy controls, the frequency
of +61A allele was higher than that of other Asian popu-
lations, with a MAF = 0.4735. Although the discrepancy
might be explained by their relatively small control sam-
ple size (n = 132), further studies were still needed to
address the difference [31].
Previous study evaluated the influence of EGF+61 G/A
to glioma risk, but no consensus had been reached
[20,32]. The effects of EGF +61 G/A allele in various can-
cers were conflicting too. Shahbazi et al. [14] showed that
G/G was significantly associated with increased malig-
nant melanoma by examining 99 controls and 135 cases.
Vishnoi et al. [33] found that G/G genotype of EGF +61A/
G was significantly associated with increased gallbladder
cancer risk by examining 126 gallbladder patients and 190
healthy controls; Goto et al. [34] found no association
between EGF +61 G/A and gastric cancer but that EGF
+61 A/A genotype showed a trend of protection by
research on 202 patients and 454 healthy controls. Kang
et al. [35] examined 432 lung cancer patients and 432
healthy age-and gender-matched control subjects and
found that +61 A/A and +61 G/A genotypes were not sig-
nificantly associated with the risk of lung cancer com-
pared with the +61 G/G genotype. Tanabe et al. [30]
examined 50 patients with cirrhosis and hepatocellular
carcinoma and 148 patients with only cirrhosis. Logistic
regression analysis demonstrated that the number of cop-
ies of G was significantly associated with increased hepa-Wang et al. BMC Cancer 2010, 10:221
http://www.biomedcentral.com/1471-2407/10/221
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tocellular carcinoma. However, the study of Gao et al.
[36] didn't find association between the EGF +61 poly-
morphism and nasopharyngeal carcinoma in Chinese
population by studying 173 patients and 206 controls, but
A/A showed a trend to increase risk. By examining 383
breast cancer patients and 500 controls, Araujo et al. [37]
found that carriers of G homozygous genotype had a
lower risk for developing breast cancer (OR = 0.68, 95CI:
0.46-1.01). A lower risk for breast cancer in G/G carriers
might be explained through EGF receptor internalization
promoted by EGF.
According to Rosenthal's criteria [38], the link between
EGF +61 G/A polymorphism and cancer is somehow
plausible. It is essential to show that the change in the
gene under study causes a relevant alteration in the func-
tion or level of the gene product, and EGF +61 G/A had
been shown to be functional [14,30,39]. The EGF-EGFR
signaling pathway performed an important role in regu-
lating cell proliferation, migration, adhesion, and inflam-
matory processes [26], the correlation between this
particular polymorphism and cancer have practical value.
However, inconsistency existed in different studies,
which may arise from many aspects. Cancer is a complex
disease, EGF +61 G/A might play different roles in differ-
ent kinds of cancers; Ethnic difference may also contrib-
ute to different disease susceptibility; Sample size must
be large enough to be convincing. Larger studies will have
greater power to detect an effect. Increasing the sample
size results in an increased frequency of detecting
marker/phenotype associations [40]. The number of
patients in most of former studies about the association
of EGF +61 G/A to cancers were less than 300, which
might lead to a different result from our study involving
677 glioma patients and 698 healthy controls. In our
paper reviewing process, a study in Northern-Chinese
population failed to detect association of EGF+61 A/G
and glioma [32], which might due to the small sample size
(168 patients). However, stratification analysis in our
study might have the decreased sample size to certain
phenotypes. When stratified by WHO, the significant
association of genotype A/A was only found in grade II
and IV. The insignificant result in grade I and III might
arise from the small sample size. Interestingly, stratifica-
tion for different smoking status suggested A allele only
Table 6: Stratified analysis of association by histology between the genotypes (alleles) and risk of glioma
Case/control Crude 
p-value
Crude 
OR(95%CI)
Adjusted 
P*-value
Adjusted 
OR*(95%CI)
Adjusted 
P**-value
Adjusted 
OR**(95%CI)
Astrocytomaa GG 121/366 1(Reference) 1(Reference) 1(Reference)
GA 112/276 0.182 1.23(0.91-1.66) 0.186 1.23(0.91-1.66) 0.092 1.32(0.96-1.81)
AA 22/51 0.335 1.31(0.76-2.24) 0.327 1.31(0.76-2.25) 0.285 1.37(0.77-2.43)
Additive 0.153 1.18(0.94-1.47) 0.152 1.18(0.94-1.48) 0.089 1.23(0.97-1.56)
G 354/1008 1(Reference) #
A 156/378 0.155 1.18(0.94-1.47)
Glioblastoma GG 94/366 1(Reference) 1(Reference) 1(Reference)
GA 99/276 0.042 1.40(1.01-1.93) 0.020 1.49(1.06-2.08) 0.024 1.51(1.06-2.17)
AA 27/51 0.006 2.06(1.23-3.46) 0.010 2.035(1.19-3.49) 0.003 2.354(1.34-4.15)
Additive 0.003 1.42(1.13-1.79) 0.002 1.45(1.14-1.84) 0.001 1.53(1.18-1.97)
G 287/1008 1(Reference) #
A 153/378 0.003 1.42(1.13-1.79)
Other gliomasb GG 83/366 1(Reference) 1(Reference) 1(Reference)
GA 94/276 0.017 1.50(1.08-2.10) 0.017 1.50(1.08-2.10) 0.028 1.96(1.08-3.58)
AA 20/51 0.059 1.73(0.98-3.06) 0.055 1.75(0.99-3.10) 0.003 1.71(1.20-2.45)
Additive 0.009 1.38(1.09-1.76) 0.008 1.39(1.09-1.77) 0.002 1.51(1.17-1.95)
G 260/1008 1(Reference) #
A 134/378 0.009 1.37(1.08-1.75)
*adjusted for age and sex
**adjusted for age, sex, fmc and smoking status
a Astrocytomas including diffuse astrocytomas, anaplastic astrocytomas, and other astrocytomas except for glioblastoma.
b Other gliomas including oligodendrogliomas, ependymomas, medulloblastoma, gliomatosis cerebri or mixed gliomas
# the adjusted OR was not appropriated for the allele comparisonWang et al. BMC Cancer 2010, 10:221
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Table 7: Stratified analysis of association by WHO between the genotypes (alleles) and risk of glioma
Case/control Crude 
p-value
Crude 
OR(95%CI)
Adjusted 
P*-value
Adjusted 
OR*(95%CI)
Adjusted 
P**-value
Adjusted 
OR**(95%CI)
I GG 25/366 1(Reference) 1(Reference) 1(Reference)
GA 28/276 0.167 1.49(0.85-2.60) 0.160 1.50(0.85-2.64) 0.041 1.92(1.03-3.61)
AA 7/51 0.123 2.01(0.83-4.88) 0.102 2.11(0.86-5.16) 0.062 2.55(0.95-6.84)
additive 0.071 1.44(0.97-2.14) 0.060 1.47(0.98-2.19) 0.018 1.69(1.09-2.61)
G 78/1008 1(Reference) #
A 42/378 0.071 1.44(0.97-2.13)
II GG 103/366 1(Reference) 1(Reference) 1(Reference)
GA 109/276 0.033 1.40(1.03-1.92) 0.036 1.40(1.02-1.91) 0.013 1.52(1.09-2.13)
AA 22/51 0.125 1.53(0.89-2.65) 0.128 1.53(0.89-2.64) 0.098 1.63(0.91-2.92)
additive 0.024 1.30(1.04-1.64) 0.026 1.30(1.03-1.63) 0.012 1.37(1.07-1.75)
G 315/1008 1(Reference) #
A 153/378 0.025 1.30(1.03-1.62)
III GG 62/366 0.484 1(Reference) 1(Reference) 1(Reference)
GA 49/276 0.821 1.05(0.70-1.57) 0.806 1.05(0.70-1.58) 0.583 1.13(0.74-1.73)
AA 5/51 0.263 0.58(0.22-1.51) 0.264 0.58(0.22-1.51) 0.276 0.56(0.19-1.60)
additive 0.555 0.91(0.66-1.25) 0.564 0.91(0.66-1.256) 0.726 0.94(0.67-1.32)
G 173/1008 1(Reference) #
A 59/378 0.559 0.91(0.66-1.25)
IV GG 108/366 1(Reference) 1(Reference) 1(Reference)
GA 119/276 0.014 1.46(1.08-1.98) 0.006 1.55(1.13-2.12) 0.006 1.59(1.14-2.22)
AA 35/51 0.001 2.33(1.44-3.76) 0.001 2.32(1.42-3.81) 0.0002 2.65(1.58-4.45)
additive 0.0002 1.50(1.21-1.87) 0.0002 1.53(1.23-1.91) <0.001 1.62(1.28-2.04)
G 335/1008 1(Reference) #
A 189/378 0.0002 1.50(1.22-1.86)
I+ II GG 128/366 1(Reference) 1(Reference) 1(Reference)
GA 137/276 0.017 1.42(1.07-1.89) 0.019 1.41(1.06-1.89) 0.003 1.59(1.17-2.16)
AA 29/51 0.056 1.63(0.99-2.68) 0.057 1.63(0.99-2.68) 0.034 1.78(1.04-3.03)
additive 0.008 1.33(1.08-1.64) 0.009 1.33(1.07-1.64) 0.002 1.43(1.14-1.79)
G 393/1008 1(Reference) #
A 195/378 0.008 1.32(1.07-1.63)
III+ IV GG 170/366 1(Reference) 1(Reference) 1(Reference)
GA 168/276 0.045 1.31(1.01-1.71) 0.025 1.36(1.04-1.78) 0.015 1.42(1.07-1.88)
AA 40/51 0.023 1.69(1.07-2.65) 0.033 1.65(1.04-2.61) 0.016 1.79(1.11-2.89)
additive 0.007 1.30(1.07-1.58) 0.007 1.31(1.08-1.60) 0.003 1.37(1.11-1.68)
G 508/1008 1(Reference) #
A 248/378 0.007 1.30(1.07-1.58)
*adjusted for age and sex
**adjusted for age, sex, fmc and smoking status
# the adjusted OR was not appropriated for the allele comparison.Wang et al. BMC Cancer 2010, 10:221
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increased the glioma risk in never-smokers. This might
be explained of small sample size in ever- and current-
smokers.
Our analysis showed the EGF +61 A allele may increase
the risk of glioma, the stratification analysis indicated
that A allele had no association with astrocytomas except
for glioblastoma. Under different histology types of astro-
cytomas, glioblastoma, and other gliomas, the statistical
power was 0.954, 0.952, and 0.920, respectively. For dif-
ferent grade of glioma, the power over 80% was only
found in WHO IV, as well as in low grade and high grade
gliomas. When adjusted for sex, age, fmc, smoking status,
the glioma grade I risk significantly increased under addi-
tive genetic model(the power was only 0.743). However,
Costa et al. [20] reported a significant association of the
G variant with an increased risk of not only gliomas but
also glioblastomas and oligodendroglial tumors in Portu-
gal. Lanuti et al. [41] found that the association between
EGF +61A/G and esophageal adenocarcinoma risk in ear-
lier-stage patients might suggest that the G/G genotype
was associated with a less aggressive phenotype, parallel-
ing lung cancer where individuals with EGF pathway
driven tumors seem to have fewer molecular alterations
[42,43]; Consider the different allele frequency between
Asians and Caucasians, further studies are needed to
explore the role of EGF +61 G/A polymorphism in cancer
development in different populations.
Cigarette smoking is a plausible behavioral exposure
that might modulate glioma risk, but no overall associa-
tion between glioma risk and cigarette smoking among
either men or women [44,45]. The number of research on
the role of smoking in glioma susceptibility was relatively
small compared to other cancers such as lung cancer.
Excision repair cross-complementing group 1 (ERCC1) is
the lead enzyme in the nucleotide excision repair process.
Stratified analyses revealed that the A/A genotype of
ERCC1 8092C > A polymorphism was a risk factor in
nonsmokers, but a protective factor in heavy smokers
when compared with the C/C genotype [46]. No study
had investigated the association between EGF polymor-
phism and the risk of glioma under different smoking sta-
tus. In our study, the genotype-smoking interaction was
insignificant. We also calculated the power of the stratifi-
cation analysis by smoking status. The result showed that
the power was 0.964 in never-smokers, which was of
strong ability to test the association between EGF +61 G/
A and glioma. However, in ever- and current-smokers,
the power was 0.421 and 0.550, respectively. It is possible
that the insignificant results in ever- and current-smokers
might attributable to relatively small number of subjects.
Additional studies with more subjects will be needed.
Our study included a relatively large sample size from a
homogeneous population of the same ethnicity. However,
several limitations in our study need to be addressed. The
association between EGF +61 SNP (rs4444903) and risk
of gliomas is biologically plausible, since EGF performs a
very important role in the proliferation, migration, and
differentiation [11]. However, only one SNP in EGF was
examined in our study. It remains uncertain whether the
rs4444903 is in strong LD with a causative variant located
inside or near the EGF locus. Secondly, the association
between EGF +61A/G and glioma risk was controversial
in our study and Caucasions [20], Thus, studies with eth-
nically diverse populations are warranted to confirm our
findings and to further elucidate the significance of the
polymorphism in the development of gliomas. Finally,
further functional experiments are therefore necessary to
test the hypotheses.
Conclusions
In conclusion, we demonstrated that the variant geno-
types of G/A and A/A were associated with a significantly
increased risk of glioma, especially glioblastma, when
compared with wild-type homozygote G/G. Whether
there were association between EGF +61 G/A and grade I
and III glioma deserved further study, as well as EGF gene
- smoking interaction. To our knowledge, this is the first
study to investigate the potential association between the
EGF +61 G/A polymorphism and gioma in a Chinese
population from east China.
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